Hikma receives FDA approval for Fluphenazine Decanoate Injection
5/4/2016 12:00:00 AM
News Icon Image

Hikma receives FDA approval for Fluphenazine Decanoate Injection


London, 4 May 2016 –  Hikma Pharmaceuticals PLC (Hikma) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its supplemental Abbreviated New Drug Application (sANDA) for Fluphenazine Decanoate Injection USP, 125mg/5 mL (25 mg/mL)  multiple-dose vial has been approved by the U.S. Food and Drug Administration (FDA).


Flphenazine Deconate Injection is a neuroleptic drug used in the treatment of chronic pysychosis. According to IMS Health, sales of Fluphenazine Deconate Injection in the US market were approximately $23 million for the 12 months ending March 2016.


Said Darwazah, Chairman and CEO of Hikma, said, “We are very pleased this product has been approved for the US market. We continue to leverage our strong R&D, regulatory and high-quality manufacturing capabilities, and remain committed to prioritising the re-introduction of Bedford products for patients in need.”


-- ENDS --

Hikma Pharmaceuticals PLC

 Susan Ringdal, VP Corporate Strategy and Investor Relations 
 +44 (0)20 7399 2760/ +44 7776 477050
 Zeena Murad, Investor Relations Manager
 +44 (0)20 7399 2768/ +44 7771 665277


FTI Consulting

 Ben Atwell/ Matthew Cole           
+44 (0)20 3727 1000 


About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Injectables”, “Branded” and “Generics”, based principally in the United States, the Middle East and North Africa (MENA) and Europe.  In 2015, Hikma achieved revenues of $1,440 million and profit attributable to shareholders of $252 million.  

  • West-Ward Pharmaceuticals Corp.

    401 Industrial Way West

    Eatontown, New Jersey 07724-2206

  • hikma
  • West-Ward Pharmaceuticals Corp. is a subsidiary of Hikma Pharmaceuticals PLC

  • VAWD Logo
  • 2009-Current West-Ward Pharmaceuticals Corp. Memphis’ distribution center is the first distribution center to be awarded “Verified-Accredited Wholesale Distributors® (VAWD®) accreditation” by The National Association of Boards of Pharmacy® (NABP®).

    Click Here for more information